吉西他滨
前药
药代动力学
药理学
核苷类似物
医学
药品
肿瘤科
核苷
化疗
内科学
化学
立体化学
作者
Bhoomika Pandit,Maksim Royzen
出处
期刊:Genes
[MDPI AG]
日期:2022-03-05
卷期号:13 (3): 466-466
被引量:32
标识
DOI:10.3390/genes13030466
摘要
Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistance have limited its efficacy. Different prodrug strategies have been explored in recent years, seeking to obtain better pharmacokinetic properties, efficacy, and safety. Different drug delivery strategies have also been employed, seeking to transform gemcitabine into a targeted medicine. This review will provide an overview of the recent developments in gemcitabine prodrugs and their effectiveness in treating cancerous tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI